首页> 外文OA文献 >Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
【2h】

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

机译:抗HER2单克隆和双特异性癌症治疗的开发与临床应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results.
机译:摘要Her2靶向免疫疗法由单克隆抗体(例如曲妥珠单抗,Pertuzumab),双特异性抗体(例如MM-111,Ertumaxomab)和武装有抗HER2双特异性抗体(HER2BI-AATC)的活化T细胞。 Trastuzumab是一种治疗HER2阳性转移性乳腺癌的经典药物。 Pertuzumab,Trastuzumab和PAClitaxel的合并应用已被提出为HER2阳性晚期乳腺癌的标准治疗。对抗HER2抗体的抗性导致疾病进展。 HER2针对这些患者可能是一个有希望的治疗方法。 Ertumaxomab增强了免疫效应细胞和肿瘤细胞的相互作用。 MM-111同时绑定到HER2和HER3并阻止下游信令。此外,Her2bi-AATC也是HER2阳性癌症的替代治疗方法。在本次审查中,我们总结了近期HER2靶向单克隆抗体(TRASTUZUMAB,PERTUZUMAB和T-DM1)和双特异性抗体(MM-111,ERTUMAXOMAB和HER2BI-AATC)的进步,特别关注临床试验结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号